<DOC>
	<DOCNO>NCT01506414</DOCNO>
	<brief_summary>The purpose study determine whether Recombinant Human Thrombopoietin ( rh-TPO ) combination Rituximab effective safe management Steroid-Resistant/Relapsed Immune Thrombocytopenia ( ITP ) .</brief_summary>
	<brief_title>Recombinant Human Thrombopoietin Combination With Rituximab Immune Thrombocytopenia ( ITP )</brief_title>
	<detailed_description>Rituximab give intravenously dose 100 mg weekly 4 consecutive week ( Day 1 , 8 , 15 , 22 ) . Rh-TPO ( TPIAOTM , product Sunshine Pharmaceutical Co Ltd , China , approve China State Food Drug Administration ) give subcutaneously dose 1.0 μg/kg（300u/kg）for 14 day ( Day 1-14 ) . Platelet count ( PC ) monitor every three four day day 22 , follow test every week . Platelet transfusion administer patient active bleeding symptom whose PC &lt; 10×10^9/L . Patients follow 3 month , adverse effect record period treatment follow-up .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Meet diagnostic criterion immune thrombocytopenia . 2 . Untreated hospitalized patient , may male female , age 18 ~ 80 year . 3 . To show platelet count &lt; 30×10^9/L , bleed manifestation . 4 . Willing able sign write informed consent . 1 . Received chemotherapy anticoagulant drug affect platelet count within 3 month screen visit . 2 . Received secondline ITPspecific treatment ( eg , cyclophosphamide , 6mercaptopurine , vincristine , vinblastine , etc ) within 3 month screen visit . 3 . Received highdose steroid IVIG 3 week prior start study . 4 . Current HIV infection hepatitis B virus hepatitis C virus infection . 5 . Severe medical condition ( lung , hepatic renal disorder ) chronic ITP . Unstable uncontrolled disease condition relate impacting cardiac function ( e.g. , unstable angina , congestive heart failure , uncontrolled hypertension cardiac arrhythmia ) 6 . Female patient nurse pregnant , may pregnant , contemplate pregnancy study period . 7 . Have know diagnosis autoimmune disease , establish medical history laboratory finding positive result determination antinuclear antibody , anticardiolipin antibody , lupus anticoagulant direct Coombs test . 8 . Patients deem unsuitable study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Purpura</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
</DOC>